The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls
Open accessAbstract
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence. Despite intergroup clinical trials conducted in Europe and North America, outcomes for high risk patients with this disease have not significantly improved in the last several decades, and survival of metastatic or relapsed disease remains extremely poor. Accrual into new clinical trials is slow and difficult, so in vitro cell-line research and in vivo xenograft models present an attractive alternative for preclinical research for this cancer type. Currently, 30 commonly used human RMS cell lines exist, with differing origins, karyotypes, histologies, and methods of validation. Selecting an appropriate cell line for RMS research has important implications for outcomes. There are also potential pitfalls in using certain cell lines including contamination with murine stromal cells, cross-contamination between cell lines, discordance between the cell line and its associated original tumor, imposter cell lines, and nomenclature errors that result in the circulation of two or more presumed unique cell lines that are actually from the same origin. These pitfalls can be avoided by testing for species-specific isoenzymes, microarray analysis, assays for subtype-specific fusion products, and short tandem repeat analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The pediatric preclinical testing program: Description of models and early testing results
Houghton, P. J., Morton, C. L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E. A., Zhang, W., Lock, R., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21078 · Cited by 480
Short tandem repeat profiling provides an international reference standard for human cell lines
Masters, J. R., Thomson, J. A., Daly-Burns, B., Reid, Y. A., Dirks, W. G., Packer, P., Toji, L. H., Ohno, T., Tanabe, H., Arlett, C. F., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121616198 · Cited by 478 · cited 2×
“and low cost of this method are the strengths supporting its use as a standard of cell line authentication (87).”
MethodFalse leukemia–lymphoma cell lines: an update on over 500 cell lines
Drexler, H. G., Dirks, W. G., Matsuo, Y., & MacLeod, R. A. F. (2003) · Leukemia · doi:10.1038/sj.leu.2402799 · Cited by 202
Cancer cell line identification by short tandem repeat profiling: power and limitations
Parson, W., Kirchebner, R., Mühlmann, R., Renner, K., Kofler, A., Schmidt, S., & Kofler, R. (2005) · The FASEB Journal · doi:10.1096/fj.04-3062fje · Cited by 129
Verification and Unmasking of Widely Used Human Esophageal Adenocarcinoma Cell Lines
Boonstra, J. J., van Marion, R., Beer, D. G., Lin, L., Chaves, P., Ribeiro, C., Pereira, A. D., Roque, L., Darnton, S. J., Altorki, N. K., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp499 · Cited by 127 · cited 1×
“In addition, three esophageal adenocarcinoma cell lines were recently found to derive from other tumors (86).”
Background
Cited by
Yu, P. Y., Gardner, H. L., Roberts, R., Cam, H., Hariharan, S., Ren, L., LeBlanc, A. K., Xiao, H., Lin, J., Guttridge, D. C., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0181885 · Cited by 17
Metadata
- Authors
- Hinson, A. R. P., Jones, R., Crose, L. E. S., Belyea, B. C., Barr, F. G., & Linardic, C. M.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 3
- Pages
- 183-183
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2076819367
- Cited by
- 192
- References
- 5
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls. https://app.cochat.ai/papers/10.3389/fonc.2013.00183
- The paper
- Hinson, A. R. P., Jones, R., Crose, L. E. S., Belyea, B. C., Barr, F. G., & Linardic, C. M. (2013). Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls. Frontiers in Oncology. https://doi.org/10.3389/fonc.2013.00183
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.